Patent 9102671 was granted and assigned to Novartis on August, 2015 by the United States Patent and Trademark Office.
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.